En Es
Categories

Industry News

Global Lateral Flow Assay Market to Exceed 8 Billion by 2022

By Labmedica International staff writers
08 Sep 2017

Image: The global lateral flow assay market is projected to grow to USD 8.24 billion by 2022 (Photo courtesy of Alere).The global lateral flow assay market is projected to grow at a CAGR of 8.2% from USD 5.55 billion in 2017 to USD 8.24 billion by 2022, driven mainly by the high prevalence of infectious diseases worldwide, rapidly growing geriatric population, growing demand for point-of-care (POC) testing, and rising use of home-based lateral flow assay devices. These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on product, the kits & reagents segment held the largest market share in 2016, due to the increasing application of lateral flow kits & reagents for POC testing, growing burden of chronic diseases, and increasing use of lateral flow kits in home care. On the basis of application, the clinical/POC testing segment accounted for the largest share of the market in 2016, led by rise in population levels and prevalence of chronic diseases, growing pressure to reduce healthcare costs, and increasing demand for patient-centric care. Based on end-user, the hospitals and clinics segment accounted for the largest share of the market in 2016, mainly due to technological advancements, increasing adoption of POC testing, innovative technologies and devices, and growing patient inclination toward fast and early diagnosis.

Geographically, North America held the largest market share in 2016, primarily due to the presence of its highly developed healthcare system, rising geriatric population, increasing incidence of chronic diseases, quick adoption of new innovative products, and a large number of lateral flow assay kits manufacturing companies in this region. However, reluctance among doctors and patients to change existing diagnostic procedures, implementation of excise duty by the US government, and stringent & time-consuming regulatory policies are restraining the growth of the lateral flow assay market.

Alere Inc. (Waltham, MA, USA) dominated the global lateral flow assay market in 2016 due to its diversified product portfolio of lateral flow assay kits and readers, as well as innovative contributions to the lateral flow assay market. Over the years, the company has developed innovative lateral flow assay products for various medical applications, such as POC testing products that make workflows more efficient and provide quality test results. The company has a strong manufacturing and distribution network across the globe, which allows it to serve customers across the Americas, Africa, Europe, the Middle East, and Asia-Pacific.



E-mail Print
FaceBook Twitter Google+ Linked in

Alere

Develops rapid point-of-care diagnostics that focus on infectious disease, cardiology, oncology, drugs of abuse, and women's health.
More info

Additional news

21 Nov 2017
Algorithm Outperforms Radiologists in Detecting Pneumonia on X-Rays
A deep learning algorithm developed by researchers from the Stanford University that evaluates chest X-rays for signs of disease has outperformed expert radiologists at diagnosing pneumonia in just over a month of its development. A paper about the algorithm named CheXNet, which can diagnose up to 14 types of medical conditions, was published November 14 on the open-access, scientific preprint website arXiv.
Read More
21 Nov 2017
Philips and Nuance to Bring AI Directly into Radiology Reporting
Health technology company Royal Philips and Nuance Communications, Inc., a provider of intelligent voice and language solutions, will jointly bring artificial intelligence-based (AI-based) image interpretation and reporting capabilities to radiologists.
Read More
21 Nov 2017
Top 4 Trends Impacting Use of VR in Surgery
Over the next few years, the market for virtual reality technologies in healthcare could reach almost USD 1 billion dollars as the use of refined virtual reality systems can help overcome the limitations of advanced surgery procedures. These are the latest findings of Kalorama Information, an independent medical market research firm.
Read More
20 Nov 2017
FDA-Approved Pill Tracks Patient Ingestion of Medication
The U.S. Food and Drug Administration (FDA) has approved Abilify MyCite (aripiprazole tablets with sensor), a pill that digitally tracks if patients have ingested their medication. Abilify MyCite is the first drug in the U.S. with a digital ingestion tracking system and has an ingestible sensor embedded in it that records that the medication was taken. The product has been approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.
Read More
20 Nov 2017
Blood Test Uses AI to Detect Peripheral Artery Disease
Researchers from the Massachusetts General Hospital and Prevencio, Inc. have developed a simple new blood test which accurately diagnoses significant Peripheral Artery Disease (PAD), a circulatory problem in which plaque-narrowed arteries reduce blood flow to a patient’s limbs and kidneys. According to the data presented at American Heart Association 2017 Scientific Sessions, the test could be used as a gatekeeper to imaging or invasive testing, thereby reducing cost and exposures to intravenous contrast and/or ionizing radiation.
Read More
14 Nov 2017
Augmented Reality Glasses Help Surgeons Operating on Tumors
Researchers at the Fraunhofer Institute for Computer Graphics Research IGD, in collaboration with The Clinic for Dermatology at Essen University Hospital and Trivisio Prototyping GmbH, have developed 3D-ARILE, an augmented reality (AR) system that provides doctors with a navigation aid for lymph node removal. The novel system superimposes a virtual image of the exact position of lymph nodes using data glasses. This allows surgeons to identify the precise location of the affected lymph nodes, enabling them to be completely removed.
Read More
14 Nov 2017
VR in Healthcare Market to Reach USD 4.9 Million by 2023
Augmented and virtual reality in the healthcare market is expected to grow at a CAGR of 36.6% from USD 769.2 million in 2017 to USD 4,997.9 million by 2023, driven by the rising penetration of connected devices in the healthcare sector, increased investment in augmented reality (AR) and virtual reality (VR) healthcare, and the growing need to reduce healthcare costs.
Read More
13 Nov 2017
Zebra Medical Vision to Enable Radiology Algorithms on Google Cloud
Zebra Medical Vision, a deep learning imaging analytics company, will be enabling all its current and future radiology algorithms on the Google Cloud as part of its new AI1 offering for global health providers.
Read More
13 Nov 2017
China Healthcare Market to Reach USD 1 Trillion by 2020
China's healthcare market is projected to grow at a whopping CAGR of about 12% from USD 357 billion in 2011 to USD 1 trillion by 2020, driven by the country’s favorable demographic trends, continued urbanization, growing disease burden, economic expansion, and rising income levels providing access to treatments. These are the latest findings of McKinsey & Company, a global management consulting firm.
Read More
Copyright © 2000-2017 TradeMed.com. All rights reserved. | Terms And Conditions